AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

Companies with late-stage cell and gene therapies

32 companies hold rights to 28 cell and gene therapies (cell therapies, gene therapies and gene editing) that are in Phase 3, Phase 2/3 or filed for approval. Sorted by the number of such drugs, then by name. Approved drugs are not counted. The full directory, with financials, is on the companies page.

BiologicsSmall moleculesCell and gene therapiesRNA and oligonucleotide drugsPeptide drugs
Late-stage cell and gene therapies, by developer
CompanyTickerLate-stageDrugs (stage, indications)
REGENXBIO Inc.RGNX3Clemidsogene lanparvovec (Phase 3, Mucopolysaccharidosis Type II); Surabgene lomparvovec (Phase 3, Age-Related Macular Degeneration); RGX-202 (Phase 2/3, Duchenne Muscular Dystrophy)
Nippon Shinyaku45162Clemidsogene lanparvovec (Phase 3, Mucopolysaccharidosis Type II); deramiocel (Phase 3, Heart Failure, Duchenne Muscular Dystrophy)
AbbVieABBV1Surabgene lomparvovec (Phase 3, Age-Related Macular Degeneration)
AnGes45631Beperminogene perplasmid (HGF plasmid) (Phase 3, Atherosclerotic Cardiovascular Disease)
Artgen BiotechABIO1Neovasculgen (Phase 2/3, Atherosclerotic Cardiovascular Disease)
AstraZenecaAZN1AZD0120 (Phase 3, Multiple Myeloma, Systemic Lupus Erythematosus, Rheumatoid Arthritis and more)
BayerBAYN1Bemdaneprocel (MSK-DA01) (Phase 3, Parkinson's Disease)
Beijing Northland Biotech—1NL003 (Phase 3, Atherosclerotic Cardiovascular Disease)
BioCardiaBCDA1CardiAMP (Phase 3, Heart Failure, Ischemic Heart Failure)
BlueRock Therapeutics—1Bemdaneprocel (MSK-DA01) (Phase 3, Parkinson's Disease)
Bristol-Myers SquibbBMY1Arlocabtagene autoleucel (Phase 3, Multiple Myeloma)
Candel Therapeutics, Inc.CADL1Aglatimagene Besadenovec (Phase 3, Non-Small Cell Lung Cancer)
Capricor TherapeuticsCAPR1deramiocel (Phase 3, Heart Failure, Duchenne Muscular Dystrophy)
Cartesian Therapeutics, Inc.RNAC1Descartes-08 (Phase 3, Myasthenia Gravis, Dermatomyositis)
EHL Bio—1ADSTEM (Phase 3, Atopic Dermatitis)
Eli LillyLLY1Ixoberogene soroparvovec (Phase 3, Wet Age-Related Macular Degeneration)
Gilead SciencesGILD1Anitocabtagene autoleucel (Phase 3, Multiple Myeloma)
Grünenthal GmbH—1rexlemestrocel-L (Phase 3, Heart Failure, Chronic Low Back Pain)
HELP Therapeutics—1HiCM-188 (allogeneic iPSC-cardiomyocytes) (Phase 3, Heart Failure)
IASO Biotherapeutics—1Equecabtagene autoleucel (Phase 3, Multiple Myeloma)
Jiangsu Topcel-KH Pharmaceutical—1TH-SC01 (Phase 3, Crohn's Disease)
Juno Therapeutics, Inc.—1Arlocabtagene autoleucel (Phase 3, Multiple Myeloma)
Lyell Immunopharma, Inc.LYEL1Rondecabtagene autoleucel (Phase 3, Large B-Cell Lymphoma)
MesoblastMESO1rexlemestrocel-L (Phase 3, Heart Failure, Chronic Low Back Pain)
Opus Genetics, Inc.IRD1OPGx-LCA5 (Phase 3, Leber Congenital Amaurosis)
ProKidneyPROK1Rilparencel (Phase 3, Chronic Kidney Disease)
Regend Therapeutics—1REGEND001 (Phase 3, Chronic Obstructive Pulmonary Disease)
Regeneron PharmaceuticalsREGN1Nexiguran ziclumeran (Phase 3, Transthyretin Amyloidosis with Cardiomyopathy)
Tasly Pharmaceutical Group6005351rexlemestrocel-L (Phase 3, Heart Failure, Chronic Low Back Pain)
TScan Therapeutics, Inc.TCRX1TSC-101 (Phase 3, Hematologic Malignancies)
TuHURA BiosciencesHURA1IFx-2.0 (Phase 2/3, Merkel Cell Carcinoma)
Vertex PharmaceuticalsVRTX1Zimislecel (Phase 3, Type 1 Diabetes)

Stage is the furthest stage the drug has reached in any indication. Kind follows each drug's recorded modality; a drug whose modality is not recorded is left out.